Traws Pharma reports positive H5N1 ferret model data for tivoxavir marboxil

Traws Pharma, Inc.

Single oral dose of tivoxavir marboxil increased survival and reduced viral burden in lungs and nasal tissues in ferrets.
Data consistent with December 2024 murine model results; non-human primate study expected Q1 2025.
Company plans to approach FDA for accelerated approval under the Animal Rule after primate data.
Virtual investor update on bird flu program scheduled for March 31, 2025.
CEO Werner Cautreels and former CDC director Robert Redfield comment on urgency of bird flu threat.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.